National Institute of Arthritis and Musculoskeletal and Skin Diseases NIAMS

Bethesda, MD, United States

National Institute of Arthritis and Musculoskeletal and Skin Diseases NIAMS

Bethesda, MD, United States
SEARCH FILTERS
Time filter
Source Type

O'Mara A.,U.S. National Cancer Institute | Rowland J.H.,U.S. National Cancer Institute | Greenwell T.N.,U.S. National Institutes of Health | Wiggs C.L.,U.S. National Institutes of Health | And 34 more authors.
American Journal of Physical Medicine and Rehabilitation | Year: 2017

One in five Americans experiences disability that affects their daily function because of impairments in mobility, cognitive function, sensory impairment, or communication impairment. The need for rehabilitation strategies to optimize function and reduce disability is a clear priority for research to address this public health challenge. The National Institutes of Health (NIH) recently published a Research Plan on Rehabilitation that provides a set of priorities to guide the field over the next 5 years. The plan was developed with input from multiple Institutes and Centers within the NIH, the National Advisory Board for Medical Rehabilitation Research, and the public. This article provides an overview of the need for this research plan, an outline of its development, and a listing of six priority areas for research. The NIH is committed to working with all stakeholder communities engaged in rehabilitation research to track progress made on these priorities and to work to advance the science of medical rehabilitation. © Wolters Kluwer Health, Inc. All rights reserved.


Balow Jr. J.E.,National Human Genome Research Institute NHGRI | Ryan J.G.,National Human Genome Research Institute NHGRI | Chae J.J.,National Human Genome Research Institute NHGRI | Booty M.G.,National Human Genome Research Institute NHGRI | And 8 more authors.
Annals of the Rheumatic Diseases | Year: 2013

Objective: To analyse gene expression patterns and to define a specific gene expression signature in patients with the severe end of the spectrum of cryopyrin-associated periodic syndromes (CAPS). The molecular consequences of interleukin 1 inhibition were examined by comparing gene expression patterns in 16 CAPS patients before and after treatment with anakinra. Methods: We collected peripheral blood mononuclear cells from 22 CAPS patients with active disease and from 14 healthy children. Transcripts that passed stringent filtering criteria (p values ≤ false discovery rate 1%) were considered as differentially expressed genes (DEG). A set of DEG was validated by quantitative reverse transcription PCR and functional studies with primary cells from CAPS patients and healthy controls. We used 17 CAPS and 66 non-CAPS patient samples to create a set of gene expression models that differentiates CAPS patients from controls and from patients with other autoinflammatory conditions. Results: Many DEG include transcripts related to the regulation of innate and adaptive immune responses, oxidative stress, cell death, cell adhesion and motility. A set of gene expression-based models comprising the CAPS-specific gene expression signature correctly classified all 17 samples from an independent dataset. This classifier also correctly identified 15 of 16 postanakinra CAPS samples despite the fact that these CAPS patients were in clinical remission. Conclusions: We identified a gene expression signature that clearly distinguished CAPS patients from controls. A number of DEG were in common with other systemic inflammatory diseases such as systemic onset juvenile idiopathic arthritis. The CAPS-specific gene expression classifiers also suggest incomplete suppression of inflammation at low doses of anakinra.


Subramanian V.,University of Massachusetts Medical School | Knight J.S.,University of Michigan | Parelkar S.,University of Massachusetts Medical School | Anguish L.,Cornell University | And 3 more authors.
Journal of Medicinal Chemistry | Year: 2015

Protein arginine deiminases (PADs) catalyze the post-translational hydrolysis of arginine residues to form citrulline. This once obscure modification is now known to play a key role in the etiology of multiple autoimmune diseases (e.g., rheumatoid arthritis, multiple sclerosis, lupus, and ulcerative colitis) and in some forms of cancer. Among the five human PADs (PAD1, -2, -3, -4, and -6), it is unclear which isozyme contributes to disease pathogenesis. Toward the identification of potent, selective, and bioavailable PAD inhibitors that can be used to elucidate the specific roles of each isozyme, we describe tetrazole analogs as suitable backbone amide bond bioisosteres for the parent pan PAD inhibitor Cl-amidine. These tetrazole based analogs are highly potent and show selectivity toward particular isozymes. Importantly, one of the compounds, biphenyl tetrazole tert-butyl Cl-amidine (compound 13), exhibits enhanced cell killing in a PAD4 expressing osteosarcoma bone marrow (U2OS) cell line and can also block the formation of neutrophil extracellular traps. These bioisosteres represent an important step in our efforts to develop stable, bioavailable, and selective inhibitors for the PADs. © 2015 American Chemical Society.

Loading National Institute of Arthritis and Musculoskeletal and Skin Diseases NIAMS collaborators
Loading National Institute of Arthritis and Musculoskeletal and Skin Diseases NIAMS collaborators